In November 2020, the National Institutes of Health announced the clinical investigators and institutions that will lead four HIV/AIDS clinical trials networks over the next seven years to conduct the innovative, efficient clinical research needed to accelerate progress against the HIV pandemic. NIAID also awarded grants to 35 U.S. and international institutions selected as HIV/AIDS clinical trials units (CTUs).
Every seven years, NIH competitively renews its funding of the HIV/AIDS clinical trials networks. NIH began the current renewal process in 2017, embarking on conversations with stakeholders and the research community to define the questions that will drive the next wave of HIV treatment and prevention innovation, and set in motion the process by which we may seek answers to those questions. These conversations helped shape the focus and priorities of NIH’s HIV/AIDS clinical trials networks through 2027.
In January 2019, NIH released six Funding Opportunity Announcements (FOAs) inviting applications on HIV prevention, therapeutic, and vaccine networks; laboratory centers; and statistical and data management centers. In May 2019, NIH released a FOA for HIV/AIDS CTUs. Following peer review of applications responsive to these FOAs, NIH awarded a total of 47 cooperative agreements in November 2020.
Learn more about the HIV/AIDS clinical trials networks and the network refinement process with the resources and information available on this site. The following resources may be of particular interest:
- NIAID News Release: NIH Announces Restructured HIV Clinical Trials Networks
- Clinical Trials Units and Clinical Research Sites
- Q&A on Refining NIH’s HIV Clinical Trials Enterprise